drugset / Trial / NCT05187403

A Study of Laquinimod Eye-drops in Healthy Participants

NCT05187403

Phase 1 Completed 54 enrolled Active Biotech AB
RandomizedSequentialTriple-blindTreatment

Summary

This is a Phase 1 randomized, double-masked, placebo-controlled study performed with healthy participants to assess the safety and tolerability of laquinimod eye-drops.

Timeline

Start
2021-12-09
Primary completion
2023-01-19
Completion
2023-01-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Laquinimod Small molecule Other

Indications